Study S000793

A Randomized Double Blind, Placebo-controlled Clinical Trial to Assess the Effects of Taspoglutide (RO5073031) on Cardiovascular Outcomes in Subjects With Inadequately Controlled Type 2 Diabetes and Established Cardiovascular Disease

ClinicalTrials.gov record

Registration

Registration: NCT01018173
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 2118
Start: 2010-01
Primary completion: 2011-01
Lead sponsor: Hoffmann-La Roche
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG:placebo; DRUG:taspoglutide
Results posted: FALSE
Secondary identifiers: OTHER:2009-014986-22; NIH:2009

Registered primary outcomes

Time to cardiovascular composite primary endpoints [event-driven, cardiovascular assessments weeks 1,4,12 and every 3 to 4 months thereafter]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.